Medtronic reports Q3 earnings, sees diabetes growth
By HME News Staff
Updated 12:16 PM CST, Tue February 17, 2026
GALWAY, Ireland – Medtronic reported revenue of $9 billion for its third quarter of fiscal year 2026 (FY26), which ended Jan. 23, 2026. Of that, diabetes business revenue was $796 million, an increase of 14.8% as reported and 8.3% organic, led by double-digit strength in international markets. In May 2025, Medtronic announced it would separate its diabetes business into a new standalone company, which represented 8% of revenue and 4% of segment operating profit in fiscal year 2025. "Q3 marks another strong quarter, delivering 6% organic revenue growth, ahead of guidance, demonstrating the strength of our portfolio," said Geoff Martha, Medtronic chairman and CEO. "By unlocking new markets and investing in high-growth opportunities, we are accelerating performance across the company. Our innovation pipeline and portfolio breadth give us confidence in our ability to sustain long-term growth. It's an exciting time for Medtronic."
Comments